Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06485089 · ClinicalTrials.gov registry record

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

A clinical trial of Obesity and Breast Cancer Risk, sponsored by University of Kansas Medical Center.

Active
Registry status
20
Enrollment target
2
Study locations

NCT06485089 is a study of Obesity and Breast Cancer Risk that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 20 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06485089, a study of Obesity and Breast Cancer Risk, is active but no longer recruiting, sponsored by University of Kansas Medical Center.

ACTIVE NOT RECRUITING
Registry status
20 participants
Enrollment target
2
Study locations

Study Summary

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

Interventions

  • DRUG tirzepatide

Study Locations (2)

Kansas

  • University of Kansas Medical Center - Kansas City
  • University of Kansas Medical Center Breast Cancer Prevention Center - Westwood

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-09-14
Est. Completion 2026-04

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT06485089

The ClinicalTrials.gov registry entry for NCT06485089 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which tirzepatide is the first listed.

NCT06485089 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT06485089 about?

NCT06485089 is a clinical study titled "Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers". Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

What is the current status of trial NCT06485089?

This trial is currently active not recruiting. The enrollment target is 20 participants. The study started on 2024-09-14. Estimated completion is 2026-04.

What conditions does trial NCT06485089 study?

This clinical trial studies the following conditions: Obesity, Breast Cancer Risk.

What interventions are being tested in trial NCT06485089?

The interventions under investigation include: tirzepatide (DRUG).

Who is sponsoring clinical trial NCT06485089?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06485089 being conducted?

This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.